July 13, 2017
Evelo Biosciences raises a $50,000,000 series B round from Flagship Pioneering.
Evelo Biosciences raises a $50,000,000 series B round from Celgene, Flagship Pioneering, GV and Mayo Clinic.
Documentaries, videos and podcasts
June 1, 2021
Evelo Biosciences, Inc., a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced the appointment of Mark Plinio as Chief Commercial Officer, effective June 14, 2021.
May 13, 2021
On-track to initiate clinical development of EDP2939 in 2022
April 20, 2021
-Evelo presents late-breaking abstract at the International Society of Atopic Dermatitis Annual Meeting- -Meaningful improvements over placebo on clinical scores, including new data released on key IGA endpoints- -Initiation of Phase 2 trial of EDP1815 in atopic dermatitis expected in 3Q 2021-
April 16, 2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
April 15, 2021
Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced the appointments of Luca Scavo as Chief Financial Officer (CFO), effective June 1, 2021, and Julie H. McHugh to its Board of Directors, effective immediately.